MDT-AP-2391
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 22.799999999999997
- os_event
- false
- age_years
- 3.66
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.256471577
- umap2_2d
- -0.773923776
- umap1_3d
- -0.198321882
- umap2_3d
- -2.696660105
- umap3_3d
- 0.155857724
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- MYC_TARGETS_V1+0.470
- G2M_CHECKPOINT+0.450
- MYC_TARGETS_V2+0.450
- OXIDATIVE_PHOSPHORYLATION+0.360
- INTERFERON_ALPHA_RESPONSE+0.240
- MTORC1_SIGNALING+0.240
- SPERMATOGENESIS+0.240
- DNA_REPAIR+0.230
- KRAS_SIGNALING_DN+0.200
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.380
- PROTEIN_SECRETION-0.300
- UV_RESPONSE_DN-0.290
- NOTCH_SIGNALING-0.280
- IL6_JAK_STAT3_SIGNALING-0.250
- TNFA_SIGNALING_VIA_NFKB-0.220
- APICAL_SURFACE-0.210
- PANCREAS_BETA_CELLS-0.210
- COMPLEMENT-0.200
- INFLAMMATORY_RESPONSE-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_HE57E1RP | Med | Medulloblastoma | 0.805 |
| 2 | TCGA-21-1083-01A-01R-0692-07 | — | cohortMD1 | 0.776 |
| 3 | BS_MMNRZ1EQ | ATRT | — | 0.769 |
| 4 | ERR2208932 | — | — | 0.769 |
| 5 | 26596228-9935-4e5d-8e41-d10f51e0f364 | — | — | 0.765 |
| 6 | C3N-00580 | — | cohortA1 | 0.764 |
| 7 | SRR17866823 | — | — | 0.742 |
| 8 | SRR8518323 | — | E | 0.740 |
| 9 | SRR8518168 | — | E | 0.740 |
| 10 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.030 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |